This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Nymox Awarded Therapeutic Discovery Grant From The U.S. Government For NX-1207 For Treatment Of BPH

HASBROUCK HEIGHTS, N.J., Nov. 3, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that it has been awarded  a grant of $244,479.25 from the U.S Government under the Qualifying Therapeutic Discovery Project for its ongoing Phase III clinical trial program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH).  The grant was the maximum allowable for an individual development program.

In order to win a grant from the Qualifying Therapeutic Discovery Project, the US Department of Health and Human Services (HHS) must first determine that the project has reasonable potential to result in new therapies to treat areas of unmet medical need; prevent, detect, or treat chronic or acute disease and conditions; reduce long-term healthcare costs in the U.S.; or significantly advance the goal of curing cancer within a 30-year period. The IRS then must determine that the project is among those projects with the greatest potential to create and sustain (directly or indirectly) high-quality, high-paying jobs in the U.S. and to advance the country's competitiveness in the fields of life, biological, and medical sciences.

NX-1207, Nymox's patented investigational drug for the treatment of BPH, is currently in pivotal Phase 3 clinical trials in the U.S. with over 70 well-known urology investigative sites participating. BPH is a chronic condition that is a common affliction of older men. There is an unmet medical need for an effective treatment for BPH without the side effects associated with currently approved drugs or the complications associated with surgical procedures.

In completed double blind Phase 1 and 2 trials to date, NX-1207 has been shown to improve the signs and symptoms of BPH, producing symptomatic improvements significantly better than that reported for approved drugs without the sexual, blood pressure, or other side effects associated with those drugs.  NX-1207 is administered by a urologist in an office setting without the need for anaesthetics or sedation or for catheterization.  Patients report little or no pain or discomfort from the procedure.  Open label follow-up studies have shown evidence of long lasting benefit from NX-1207 treatment with a significant proportion of men who received a single dose of NX-1207 reporting maintained improvement in BPH symptoms without other treatments for up to five years or more.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs